Diagnostic imaging service provider Lumexa Imaging Holdings (LMRI.US) applies for IPO in the United States, aiming to raise approximately 200 million dollars.

Lumexa Imaging Holdings, a provider of outpatient imaging diagnostic services, submitted its application for listing to the U.S. Securities and Exchange Commission (SEC) on Monday, expecting to raise up to $200 million through its initial public offering (IPO). As a nationwide provider of outpatient diagnostic imaging services, Lumexa Imaging operates 184 diagnostic centers in 13 states through wholly-owned operations and joint ventures with healthcare systems. The company offers a wide range of advanced and routine imaging services including magnetic resonance imaging (MRI), computerized tomography (CT), positron emission tomography (PET), X-ray, ultrasound, and mammography. Founded in 2018 by Charlotte Radiology and investment firm Welsh, Carson, Anderson & Stowe, the company initially had 20 centers and later expanded through 20 acquisitions and the opening of 41 new centers. Lumexa Imaging has built a diverse referral network with over 29,000 affiliated physicians covering approximately 100,000 individuals. Based in Raleigh, North Carolina, the company generated $1 billion in revenue in the 12 months ending September 30, 2025. It plans to list on the Nasdaq stock exchange under the ticker symbol LMRI and submitted a confidential filing on June 12, 2025. The joint bookrunners for the IPO include Barclays, J.P. Morgan, Jefferies Financial Group Inc., Deutsche Bank Aktiengesellschaft, Goldman Sachs, Leerink Partners, William Blair, Capital One Securities, Fifth Third Securities, Raymond James, and PNC Capital Markets. The pricing terms for the offering have not been disclosed yet.